Literature DB >> 2155791

Surgical treatment of stage-I non-seminomatous germ cell testis tumor. Final results of a prospective multicenter trial 1982-1987. Testicular Tumor Study Group.

L Weissbach1, E A Boedefeld, B Horstmann-Dubral.   

Abstract

Final results of a prospective multicenter trial are presented comparing modified (ipsilateral) and radical retroperitoneal lymph node dissection (RLND) with regard to staging accuracy, curativity, and preserved ejaculation in stage-I non-seminomatous testis tumor. In 168 patients after modified and 67 patients after radical RLND, no differences were found in relapse rates (17 and 15%, respectively; median follow-up 30 months); in frequency of retroperitoneal relapse (2.4 and 1.5%, respectively), and intra-/postoperative complications (12 and 10%, respectively). Postoperative ejaculation was antegrade in 74 and 34%, (p less than 0.001), retrograde in 11 and 12% respectively. Normozoospermia was found in 50% of patients postoperatively vs. 20% preoperatively. Results are discussed in view of other alternatives. Modified RLND is considered an optimal approach to stage-I non-seminomatous germ cell testis tumor, outside specific trials.

Entities:  

Mesh:

Year:  1990        PMID: 2155791     DOI: 10.1159/000464015

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  16 in total

Review 1.  Advances in the treatment of testicular cancer.

Authors:  Hans-Georg Kopp; Markus Kuczyk; Johannes Classen; Arnulf Stenzl; Lothar Kanz; Frank Mayer; Michael Bamberg; Jörg Thomas Hartmann
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  [Retroperitoneal lymphadenectomy - pro laparoscopy].

Authors:  L Lusuardi; G Janetschek
Journal:  Urologe A       Date:  2012-05       Impact factor: 0.639

3.  Canadian consensus guidelines for the management of testicular germ cell cancer.

Authors:  Lori Wood; Christian Kollmannsberger; Michael Jewett; Peter Chung; Sebastian Hotte; Martin O'Malley; Joan Sweet; Lynn Anson-Cartwright; Eric Winquist; Scott North; Scott Tyldesley; Jeremy Sturgeon; Mary Gospodarowicz; Roanne Segal; Tina Cheng; Peter Venner; Malcolm Moore; Peter Albers; Robert Huddart; Craig Nichols; Padraig Warde
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

4.  Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma.

Authors:  Zaza Mezvrishvili; Laurent Managadze
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 5.  The evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates.

Authors:  Mark H Katz; Scott E Eggener
Journal:  World J Urol       Date:  2009-04-11       Impact factor: 4.226

Review 6.  Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection.

Authors:  Shane Pearce; Zoe Steinberg; Scott Eggener
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 7.  Retroperitoneal lymph node dissection: an update in testicular malignancies.

Authors:  K Yadav
Journal:  Clin Transl Oncol       Date:  2017-02-01       Impact factor: 3.405

8.  [Results of the randomised phase III study of the German Testicular Cancer Study Group. Retroperitoneal lymphadenectomy versus one cycle BEP as adjuvant therapy for non-seminomatous testicular tumours in clinical stage I].

Authors:  M Hartmann; R Siener; S Krege; H Schmelz; K-P Dieckmann; A Heidenreich; P Kwasny; M Pechoel; J Lehmann; S Kliesch; K-U Köhrmann; R Fimmers; L Weissbach; V Loy; C Wittekind; P Albers
Journal:  Urologe A       Date:  2009-05       Impact factor: 0.639

9.  Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis.

Authors:  Soner Guney; Nese Guney; Nurettin Cem Sonmez; Erbil Ergenekon
Journal:  Med Oncol       Date:  2008-09-26       Impact factor: 3.064

10.  [Pre- and paraclinical cooperative trials on testicular cancer. Background and overview of current trials].

Authors:  K-P Dieckmann
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.